Pre-Clinical Trials

Beta-O2 Technologies Ltd. has tested the long-term functionality of the βAir device in isogeneic (Lewis rat to Lewis rat), allogeneic (Lewis rat to Sprague-Dawley rat), and xenogeneic (rat to pig model) transplantations, in small animals (rats) and in large animals (pigs). The system has demonstrated safety and long term functionality in a non-immunosuppressed environment.

The results of the studies demonstrated:

  • The ability of the βAir device to support oxygen requirements of donor isogenic, allogenic, and xenogenic cells in a functional mode
  • The ability of the βAir device to protect isogenic, allogenic, and xenogenic implanted cells from the host immune system
  • The ability of the βAir device to achieve near-normal glucose control in diabetic animals
  • The ability of the βAir device to achieve glucose pharmacokinetics patterns in diabetic animals (rats and pigs) similar to the patterns of healthy animals